GlobeNewswire 6/8/2015 Sobi Board of Directors terminates discussions regarding non-binding proposal
GlobeNewswire 6/4/2015 Sobi's partner Biogen submits marketing authorisation application for Alprolix® (rFIXFc) in Europe
GlobeNewswire 5/27/2015 Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
GlobeNewswire 5/6/2015 Sobi publishes its Report for the First Quarter 2015
GlobeNewswire 5/4/2015 Early treatment and a longer life - new Orfadin formats meet new patient needs
GlobeNewswire 4/30/2015 Invitation - Presentation of Sobi's first quarter 2015
GlobeNewswire 4/29/2015 Sobi's Board of Directors postpones Annual General Meeting of Shareholders
GlobeNewswire 4/27/2015 Statement regarding recent speculation
GlobeNewswire 4/15/2015 Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014
GlobeNewswire 3/30/2015 Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
GlobeNewswire 2/27/2015 Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix® p...
GlobeNewswire 2/26/2015 Rare Disease Day 2015: Sobi shares study findings on HT-1 adherence in adolescent patients, to high...
GlobeNewswire 2/19/2015 Sobi publishes its Report for the Fourth Quarter and Full Year 2014
GlobeNewswire 2/12/2015 Invitation - Presentation of Sobi's fourth quarter and full year results 2014
GlobeNewswire 12/22/2014 Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease
GlobeNewswire 12/19/2014 Sobi's 2011 Long-Term incentive Programme meets all objectives
GlobeNewswire 12/9/2014 Sobi CEO Geoffrey McDonough sells a portion of 2014 incentive shares
GlobeNewswire 11/21/2014 Sobi exercises opt-in right for Elocta(TM)
GlobeNewswire 10/31/2014 Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Au...
GlobeNewswire 10/30/2014 Sobi publishes Report for the Third Quarter 2014
GlobeNewswire 10/16/2014 Invitation - Presentation of Sobi's third quarter results 2014
GlobeNewswire 10/9/2014 Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (r...
GlobeNewswire 9/22/2014 Sobi opens North American operations
GlobeNewswire 9/19/2014 Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemop...
GlobeNewswire 7/18/2014 Sobi's board of directors exercises authorisation for repurchase of shares for the purpose of securi...